Janssen hits Celltrion and Hospira with biosimilar suit

10-03-2015

Pharmaceutical company Janssen has sued drugs businesses Celltrion and Hospira in one of the first patent infringement actions brought under the Biologics Price Competition and Innovation Act (BPCIA).


Janssen, Celltrion, Hospira, Remicade, BPCIA, biosimilar

LSIPR